Press Announcements > Statement from FDA Commissioner Scott Gottlieb, M.D. on advancing the development of novel treatments for neurological conditions; part of broader effort on modernizing FDA’s new drug review programs

Press Announcements > Statement from FDA Commissioner Scott Gottlieb, M.D. on advancing the development of novel treatments for neurological conditions; part of broader effort on modernizing FDA’s new drug review programs

Statement from FDA Commissioner Scott Gottlieb, M.D. on advancing the development of novel treatments for neurological conditions; part of broader effort on modernizing FDA’s new drug review programs

New medical breakthroughs are altering how diseases are treated in ways that seemed unimaginable just a decade ago. Perhaps one of the most significant developments is the advent of new gene therapies and drugs that boost the immune system’s ability to target tumor cells. But we recognize that progress across different therapeutic areas has been uneven, including for complex neurological diseases. In part, this is because the underlying causes of severe neurological diseases may not be as well understood compared to ailments like cancer. The brain, in many respects, is the last organ system where many aspects of our understanding of the underlying biology of disease remain uncertain. Continue reading.